晚期卵巢癌间隔缓解手术期间腹膜洗涤细胞学的预后分析

新辅助化学疗法后的间隔漫画手术（IDS）是晚期卵巢癌的治疗选择。需要最佳手术才能更好地生存；但是，尽管腹膜洗涤细胞学（PWC）已被确定为预后因素，但其在ID中的全面评估仍未得到探索。因此，我们的目的是通过回顾25例晚期卵巢癌症患者的医疗记录，以回顾25例晚期新辅助化学疗法，并在2017年1月202日至6月202日之间（403. TWELVE）（40），包括残留疾病和其他因素以及其他因素以及其他因素以及其他因素以及模型的癌症抗原125（CA-125）消除速率常数K（Kelim）。其余为普华永道阴性。 PWC在IDS期间在剖腹手术中进行，此后五个（41.7％）PWC阳性和四名（30.8％）PWC阴性患者接受了贝伐单抗，这是一种抗血管内皮生长因子单克隆抗体，用于维持治疗。四个（33.3％）的PWC阳性和10（76.9％）PWC阴性患者接受了二磷酸二磷酸腺苷（ADP） - 脱纤酶聚合酶抑制剂。在接受Bevacizumab和Poly ADP-核糖聚合酶抑制剂的患者中，PWC阳性和PWC阴性的患者的总生存率和无进展生存期并没有显着差异（分别为P = 0.27和0.20）。有利和不利的Ca-125 kelim的人之间无进展生存率显着差异（p = 0.02）。多变量分析表明，最佳手术和有利的CA-125 kelim与更好的无进展生存期有关（分别为p <0.01和0.02），仅与更好的总体生存率相关（p = 0.04）。我们的发现表明，尽管ID处的PWC状态应该是决定晚期卵巢癌患者生存的因素之一，但最近的维持治疗方法的改善可能会使CA-125 Kelim和PWC状态的结合成为选择ID后选择治疗的预后因素。需要进一步的研究来验证这些结果，强调ID后维持治疗的潜在重要性，以及需要进一步研究以验证阳性PWC的临床意义。

Interval debulking surgery (IDS) following neoadjuvant chemotherapy is a treatment option for advanced ovarian cancer. Optimal surgery is required for better survival; however, while peritoneal washing cytology (PWC) has been identified as a prognostic factor, its comprehensive assessment during IDS remains unexplored. Therefore, we aimed to evaluate PWC efficacy during IDS, alongside other factors including residual disease and the modeled cancer antigen 125 (CA-125) ELIMination rate constant K (KELIM), by retrospectively reviewing the medical records of 25 patients with advanced ovarian cancer underwent neoadjuvant chemotherapy and IDS between January 2017 to June 2023.Twelve (48.0%) patients were PWC-positive, and the remainder were PWC-negative. PWC was performed at laparotomy during IDS, after which five (41.7%) PWC-positive and four (30.8%) PWC-negative patients received bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, for maintenance treatment. Four (33.3%) PWC-positive and 10 (76.9%) PWC-negative patients received poly adenosine diphosphate (ADP)-ribose polymerase inhibitors. In patients who received bevacizumab and poly ADP-ribose polymerase inhibitors, overall survival and progression-free survival did not significantly differ between those who were PWC-positive and PWC-negative (p = 0.27 and 0.20, respectively). Progression-free survival significantly differed between those with favorable and unfavorable CA-125 KELIM (p = 0.02). Multivariate analysis indicated that optimal surgery and favorable CA-125 KELIM were associated with better progression-free survival (p < 0.01 and 0.02, respectively), with only optimal surgery associated with better overall survival (p = 0.04).A positive PWC at IDS was not associated with survival in advanced ovarian cancer. Our findings indicate that although PWC status at IDS should be one of the factors determining survival in patients with advanced ovarian cancer, recent improvements in maintenance therapy may make the combination of CA-125 KELIM and PWC status a more useful prognostic factor in selecting treatment after IDS. Further studies are needed to validate these results, highlighting the potential importance of maintenance treatment after IDS and the need for further research to validate the clinical significance of a positive PWC.